Results
1 -
10 of
59
(Click
here to explore results)
- Implantable Technologies: Peptides and Small Molecules Drug Delivery, CHAPTER 5 Development of Risperidone Implant Formulations (DLP-114) for Long-term Maintenance Treatment of Schizophrenia. Gregory Watkins, Francis Martin
, 2022
, Pages 90-110
- Drug Discovery for Psychiatric Disorders, CHAPTER 3 Monoaminergic Approaches for Treatment of Schizophrenia. David P. Rotella
, 2012
, Pages 35-55
- Conference on Drug Design and Discovery Technologies, Binding Studies of Antipsychotic Drug Risperidone with β-Lactoglobulin Using Fluorimetry and Molecular Modelling. Bandoo C. Chatale, Laxmi Ananthanarayan, Mariam S. Degani
, 2020
, Pages 319-329
- Designing Multi-Target Drugs, Chapter 16 Discovery of the Anti-Psychotic Drug, Ziprasidone. John A. Lowe, III
, 2012
, Pages 263-269
- Drug Discovery for Psychiatric Disorders, CHAPTER 15 Emerging Research towards the Understanding and Treatment of Autism. Paul Wang, Rebecca Hammond, Friso Postma, Aileen Healy
, 2012
, Pages 384-415
- Implantable Technologies: Peptides and Small Molecules Drug Delivery, Contents
, 2022
, Pages P013-P019
- Implantable Technologies: Peptides and Small Molecules Drug Delivery, Subject Index
, 2022
, Pages 296-302
- Designing Multi-Target Drugs, Chapter 2 Clinical Need and Rationale for Multi-Target Drugs in Psychiatry. Mohammed Shahid
, 2012
, Pages 14-31
- Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET, Chapter 10 Alcohols and Phenols: Absorption, Distribution, Metabolism and Excretion. Zhuang Miao, R. Scott Obach
, 2010
, Pages 460-485
- Drug Discovery for Schizophrenia, CHAPTER 8 GSK3 Networks in Schizophrenia. Jivan Khlghatyan, Gohar Fakhfouri, Jean-Martin Beaulieu
, 2015
, Pages 173-201